Purpose We have treated patients with non-small-cell lung cancer (NSCLC) who developed
leptomeningeal metastases (LM) during gefitinib therapy, and then found symptomatic …

Central nervous system (CNS) metastases are a common complication in patients with
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …

The purpose of this study was to demonstrate the beneficial effect of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of leptomeningeal …

It has been demonstrated that erlotinib is effective in treating patients with brain metastasis
from non‑small‑cell lung cancer. However, the number of studies determining the erlotinib …

Purpose/Objectives Radiation therapy (RT) is the principal modality in the treatment of
patients with brain metastases (BM). However, given the activity of EGFR tyrosine kinase …

Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …

Lung adenocarcinomas are more commonly associated with brain metastases (BM).
Epidermal growth factor receptor (EGFR) mutations have been demonstrated to be both …

Introduction Previous studies suggested that epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression …

Leptomeningeal metastases (LM) occur in 5–10% of patients with solid tumors and are
associated with a dismal prognosis. We describe LM from lung adenocarcinoma harboring a …

Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …